睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

ClinicalTrials.gov 上登记的一项肺癌开放试验,由空军军医大学唐都医院牵头,本站收录的另外 2 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 3

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方空军军医大学唐都医院Tangdu Hospital西安医院页面
  2. 研究中心宁夏医科大学总医院General Hospital of Ningxia Medical University银川医院页面
  3. 研究中心中南大学湘雅二医院Second Xiangya Hospital长沙医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06864624,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. EGFR exon 20 insertion mutation confirmed by an approved local laboratory.

    入选标准第 4 条

  3. Before the first dose, there are adverse events of CTCAE > 1 grade (except for any degree of alopecia) caused by previous treatment (such as diagnostic puncture, use of other drugs, etc.).

    排除标准第 6 条

  4. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L

    入选标准第 8 条

    Platelets ≥ 100 × 109/L

    入选标准第 9 条

    Hemoglobin ≥ 9 g/dL

    入选标准第 10 条

    Total bilirubin ≤ 1.5 ×ULN; in patients with Gilbert syndrome, total bilirubin ≤ 3 × ULN

    入选标准第 11 条

    ALT≤ 2.5 × ULN and AST≤ 2.5 × ULN

    入选标准第 12 条

    Creatinine ≤ 1.5 × ULN, and creatinine clearance calculated the Cockcroft-Gault method ≥ 60 mL/min

    入选标准第 13 条

    International normalized ratio (INR) ≤ 1.5 × ULN

    入选标准第 14 条

    Partial thromboplastin time (APTT) ≤ 1.5 × ULN

    入选标准第 15 条

  5. At least one measurable target lesion according to RECIST v1.1.

    入选标准第 6 条

  6. A history of other malignant tumors other than lung cancer within 2 years (except for basal cell carcinoma of the skin or in situ cervical cancer that has been adequately treated and has no evidence of recurrence during the screening period).

    排除标准第 5 条

  7. Male patients who wish to have children should use barrier contraception (such as condoms) during the clinical trial period and 6 months after the last dose. Male patients should not donate sperm during the clinical trial period and 6 months after the last dose.

    入选标准第 16 条

    Female patients should take contraceptive measures from the start of screening to the 6 weeks after last dose, should not breastfeed, and should have a negative pregnancy test (blood or urine β-human chorionic gonadotropin) at screening.

    入选标准第 17 条

    Women who are breastfeeding or pregnant.

    排除标准第 16 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06864624,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients must understand the requirements and content of the clinical trial and provide a handwritten signed and dated informed consent.
  2. Age ≥ 18 years old.
  3. Non-small cell lung cancer confirmed by histopathology or cytology, clinical stage II, IIIA or IIIB (N2) assessed by the investigator according to AJCC 8th edition.
  4. EGFR exon 20 insertion mutation confirmed by an approved local laboratory.
  5. No disease progression in the past two weeks of signing the informed consent form and a score of 0-1 according to the ECOG criteria, and no significant progression within 2 weeks before the first dose.
  6. At least one measurable target lesion according to RECIST v1.1.
  7. Adequate bone marrow and other organ reserve:
  8. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L
  9. Platelets ≥ 100 × 109/L
  10. Hemoglobin ≥ 9 g/dL
  11. Total bilirubin ≤ 1.5 ×ULN; in patients with Gilbert syndrome, total bilirubin ≤ 3 × ULN
  12. ALT≤ 2.5 × ULN and AST≤ 2.5 × ULN
  13. Creatinine ≤ 1.5 × ULN, and creatinine clearance calculated the Cockcroft-Gault method ≥ 60 mL/min
  14. International normalized ratio (INR) ≤ 1.5 × ULN
  15. Partial thromboplastin time (APTT) ≤ 1.5 × ULN
  16. Male patients who wish to have children should use barrier contraception (such as condoms) during the clinical trial period and 6 months after the last dose. Male patients should not donate sperm during the clinical trial period and 6 months after the last dose.
  17. Female patients should take contraceptive measures from the start of screening to the 6 weeks after last dose, should not breastfeed, and should have a negative pregnancy test (blood or urine β-human chorionic gonadotropin) at screening.

排除标准:Exclusion Criteria:

  1. Patients who have received the following treatments must be excluded:
  2. Any systemic anti-tumor treatment, including radiotherapy;
  3. Other drugs in the development stage, if the medication does not exceed 28 days and has not undergone any tumor assessment, the medication must be stopped for more than 5 half-lives and the patient can be enrolled after consultation with the investigator.
  4. Traditional Chinese medicine and other drugs with strong P450 (CYP)3A4 inhibitory or inducing effects are currently being used or cannot be stopped. There must be a washout period of at least 1 week before the first dose.
  5. A history of other malignant tumors other than lung cancer within 2 years (except for basal cell carcinoma of the skin or in situ cervical cancer that has been adequately treated and has no evidence of recurrence during the screening period).
  6. Before the first dose, there are adverse events of CTCAE > 1 grade (except for any degree of alopecia) caused by previous treatment (such as diagnostic puncture, use of other drugs, etc.).
  7. History of stroke or intracranial hemorrhage within 6 months before the first dose.
  8. According to the investigator's judgment, the presence of any severe or poorly controlled systemic disease, including any of the following poorly controlled heart-related diseases or abnormalities:
  9. The resting electrocardiogram shows a calibrated QTc interval (QTcF) > 470 msec
  10. The resting electrocardiogram shows any serious abnormalities in heart rhythm, conduction or pattern, such as complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval > 250 msec
  11. Any factors that can cause QTcF prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, family history of QT syndrome or other sudden death diseases under 40 years old, or other diseases known to cause QT prolongation
  12. Suffering from atrial fibrillation (except for drug-induced and recovered after discontinuation of the drug)
  13. Myocardial infarction within 6 months before the first dose, New York Heart Association grade 2 congestive heart failure, or arrhythmias that are not well controlled by drugs
  14. Patients with a history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid hormone treatment, or any clinically active interstitial lung disease, or immune pneumonitis caused by immunotherapy.
  15. Patients with refractory nausea and vomiting, chronic gastrointestinal diseases, difficulty in swallowing medication, or previous intestinal resection that prevents adequate absorption of sunvozertinib.
  16. Women who are breastfeeding or pregnant.
  17. Patients who are allergic to the drug components of sunvozertinib.
  18. Patients who are assessed by the investigator as being unable to undergo clinical trials, unable to tolerate surgery, or who may lack compliance with clinical trials should not participate in this study.

引自 ClinicalTrials.gov, NCT06864624, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06864624,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06864624